Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03048929 · ClinicalTrials.gov registry record · Early Phase 1
Inflammation and Threat Sensitivity in PTSD
A Early Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT03048929 is a Early Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 30 participants.
The verdict
NCT03048929, a Early Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The overall goals of this study are to examine the relationship between chronic inflammation and threat and reward sensitivity, and to determine the effects of acute inflammation on threat sensitivity, in individuals with and without moderate to severe PTSD symptoms. The investigators will first conduct an observational study to examine the relationship between chronic inflammation and neural and behavioral measures of threat sensitivity. Then, the investigators will conduct a randomized, double-blind, placebo-controlled, between-subjects study to examine the effects of acute inflammation on neural and behavioral measures of threat sensitivity.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Typhoid Vi Polysaccharide Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2021-03-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03048929
The ClinicalTrials.gov registry entry for NCT03048929 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03048929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03048929 about?
NCT03048929 is a clinical study titled "Inflammation and Threat Sensitivity in PTSD". The overall goals of this study are to examine the relationship between chronic inflammation and threat and reward sensitivity, and to determine the effects of acute inflammation on threat sensitivity, in individuals with and without moderate to severe PTSD symptoms. The investigators will first con...
What is the current status of trial NCT03048929?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2019-04-01. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT03048929?
The interventions under investigation include: Placebo (BIOLOGICAL), Typhoid Vi Polysaccharide Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03048929?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.